ArticleDiscover oncology2025
Clinicopathological characteristics and molecular genetic analysis of inflammatory and nested testicular sex cord tumor: a case report and literature review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Inflammatory and Nested Testicular Sex Cord Tumors: Clinical and Molecular Characterization.Genes · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory and nested testicular sex cord tumor (IN-SCT) is a newly defined and rare variant of sex cord-stromal tumors, characterized by EWSR1::ATF1 gene fusion, prominent inflammatory infiltration, and aggressive behavior, often leading to misdiagnosis as lymphoma or seminoma. This study aims to systematically analyze the clinicopathological and molecular features of IN-SCT through a case report and comprehensive literature review, exploring its diagnostic pitfalls and therapeutic strategies. CASE PRESENTATION: A 36-year-old male presented with painless left testicular enlargement. Ultrasound revealed a 6.0 × 5.0 × 3.3 cm heterogeneous mass with irregular vascularity. Initial pathological evaluation after radical orchiectomy at an outside hospital favored a diagnosis of seminoma. However, external consultation raised suspicion of ALK-negative anaplastic large cell lymphoma (ALCL) based on CD30 immunoreactivity. Further histopathological examination at our institution revealed tumor cells arranged in nests and solid patterns, with extensive inflammatory infiltration. Immunohistochemistry (IHC) demonstrated weak positivity for inhibin-α and diffuse positivity for CD30. Fluorescence in situ hybridization (FISH) confirmed EWSR1 gene rearrangement, leading to a final diagnosis of IN-SCT. TREATMENT AND OUTCOME: The patient underwent six cycles of platinum-based chemotherapy following orchiectomy. No evidence of recurrence was observed at the 10-month follow-up.
conclusionIN-SCT is a diagnostically challenging tumor characterized by the triad of inflammatory stroma, EWSR1::ATF1 fusion, and aggressive clinical behavior. Accurate recognition of its unique features supports its classification as a distinct entity. Surgical excision followed by adjuvant chemotherapy may benefit patients with advanced disease. The distinct molecular profile of IN-SCT may provide future directions for targeted therapy and diagnostic refinement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.